January 22, 2019
Janssen Pharmaceutical and Nippon Shinyaku said on January 21 that they have entered into a copromotion agreement in Japan for Janssen’s novel oral androgen receptor inhibitor apalutamide, which is currently under regulatory review in the country. The partners will jointly...read more